文献速递免疫规划

抗聚乙二醇抗体与mRNA新冠疫苗接种后过敏反应关联的评估

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
PubMed 文献 · Vaccine · 2023-05-16

该研究比较了mRNA新冠疫苗接种后发生过敏反应的病例与无过敏反应接种者的血清抗聚乙二醇(PEG)IgE、IgG和IgM水平。结果显示,抗PEG IgE在病例组与对照组间无显著差异,且抗PEG IgG和IgM均与病例状态无关,表明抗PEG IgE并非mRNA新冠疫苗接种后过敏反应的主要机制。

要点

  • 20例过敏反应病例均为女性,其中13例住院、7例插管。
  • Moderna接种者中,抗PEG IgE在病例组为10%(1/10),对照组为27%(8/30),p=0.40。
  • 辉瑞-BioNTech接种者中,抗PEG IgE在病例组为0%(0/10),对照组为3%(1/30),p>0.99。

核心结论

  • 研究结果支持抗PEG IgE不是mRNA新冠疫苗接种后过敏反应的主要机制。

研究设计与样本

  • 选取2020年12月14日至2021年3月25日向美国疫苗不良事件报告系统报告的过敏反应病例,邀请提供血清样本。
  • 从mRNA新冠疫苗接种研究参与者中选取接种后无过敏反应且有残余血清者作为对照,按疫苗和剂次、性别及10岁年龄组以3:1比例进行频率匹配。
  • 采用双细胞术珠法(DCBA)检测抗PEG IgE,采用DCBA和聚乙二醇化聚苯乙烯珠法两种方法检测抗PEG IgG和IgM,实验室人员对病例/对照状态设盲。

主要发现

  • 所有20例病例均为女性;17例在接种第1剂后发生过敏反应,3例在接种第2剂后发生。
  • 13例(65%)住院,7例(35%)插管。
  • 病例组从接种到采血的时间长于对照组(第1剂后:中位数105天 vs 21天)。
  • Moderna接种者中,抗PEG IgE在病例组检测到1/10(10%),对照组8/30(27%)(p=0.40)。
  • 辉瑞-BioNTech接种者中,抗PEG IgE在病例组检测到0/10(0%),对照组1/30(3%)(p>0.99)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The mechanism for anaphylaxis following mRNA COVID-19 vaccination has been widely debated; understanding this serious adverse event is important for future vaccines of similar design. A mechanism proposed is type I hypersensitivity (i.e., IgE-mediated mast cell degranulation) to polyethylene glycol (PEG). Using an assay that, uniquely, had been previously assessed in patients with anaphylaxis to PEG, our objective was to compare anti-PEG IgE in serum from mRNA COVID-19 vaccine anaphylaxis case-patients and persons vaccinated without allergic reactions. Secondarily, we compared anti-PEG IgG and IgM to assess alternative mechanisms. METHODS: Selected anaphylaxis case-patients reported to U.S. Vaccine Adverse Event Reporting System December 14, 2020-March 25, 2021 were invited to provide a serum sample. mRNA COVID-19 vaccine study participants with residual serum and no allergic reaction post-vaccination ("controls") were frequency matched to cases 3:1 on vaccine and dose number, sex and 10-year age category. Anti-PEG IgE was measured using a dual cytometric bead assay (DCBA). Anti-PEG IgG and IgM were measured using two different assays: DCBA and a PEGylated-polystyrene bead assay. Laboratorians were blinded to case/control status. RESULTS: All 20 case-patients were women; 17 had anaphylaxis after dose 1, 3 after dose 2. Thirteen (65 %) were hospitalized and 7 (35 %) were intubated. Time from vaccination to serum collection was longer for case-patients vs controls (post-dose 1: median 105 vs 21 days). Among Moderna recipients, anti-PEG IgE was detected in 1 of 10 (10 %) case-patients vs 8 of 30 (27 %) controls (p = 0.40); among Pfizer-BioNTech recipients, it was detected in 0 of 10 case-patients (0 %) vs 1 of 30 (3 %) controls (p >n 0.99). Anti-PEG IgE quantitative signals followed this same pattern. Neither anti-PEG IgG nor IgM was associated with case status with both assay formats. CONCLUSION: Our results support that anti-PEG IgE is not a predominant mechanism for anaphylaxis post-mRNA COVID-19 vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Zhou ZH, Cortese MM, Fang JL, et al. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023. PMID: 37244808. doi:10.1016/j.vaccine.2023.05.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。